Novel modifications in the alkenyldiarylmethane (ADAM) series of non- nucleoside reverse transcriptase inhibitors

Journal of Medicinal Chemistry

Volumn 42, Issue 23, 1999, Pages 4861-4874

  Casimiro Garcia, Agustin ^a   Micklatcher, Mark ^a   Turpin, Jim A ^b   Stup, Tracy L ^b   Watson, Karen ^b   Buckheit, Robert W ^b   Cushman, Mark ^a  

^a PURDUE UNIVERSITY   (United States)

^b Infect Disease Research Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3',3'' DIBROMO 4',4'' DIMETHOXY 5',5'' BIS(METHOXYCARBONYL) 6,6 DIPHENYL 5 HEXENOIC ACID METHYL ESTER; ALKENYL GROUP; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS INHIBITION;

ANTI-HIV AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MICROBIAL; HEXANOIC ACIDS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032744956     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990343b     Document Type: Article

References (48)

1. Carpenter, C. C. J.; Fischl, M. A.; Hammer, S. M.; Hirsch, M. S.; Jacobsen, D. M.; Katzenstein, D. A.; Montaner, J. S. G.; Richman, D. D.; Saag, M. S.; Schooley, R. T.; Thompson, M. A.; Vella, S.; Yeni, P. G.; Volberding, P. A. Antiretroviral Therapy for HIV Infections in 1998. J. Am. Med. Assoc. 1998, 280, 78-86.
2. De Clercq, E. The Role of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Therapy of HIV-1 Infection. Antiviral Res. 1998, 38, 153-179.
3. Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Ann. Int. Med. 1998, 128, 1057-1099.
4. Tavel, J. A.; Miller, K. D.; Masur, H. Guide to Major Clinical Trials of Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients: Protease Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, and Nucleoside Reverse Transcriptase Inhihitors. Clin. Infect. Dis. 1999, 28, 643-676.
5. Cushman, M.; Golebiewski, M.; Buckheit, R. W. J.; Graham, L.; Rice, W. G. Synthesis and Biological Evaluation of an Alkenyldiarylmethane (ADAM) which Acts as a Novel Nonnucleoside HIV-1 Reverse Transcriptase Inhibitor. Bioorg. Med. Chem. Lett. 1995, 5, 2713-2716.
6. Cushman, M.; Golebiewski, W. M.; Graham, L.; Turpin, J. A.; Rice, W. G.; Fliakas-Boltz, V.; Buckheit, R. W. J. Synthesis and Biological Evaluation of Certain Alkenyldiarylmethanes as Anti-HIV-1 Agents Which Act as Non-Nucleoside Reverse Transcriptase Inhibitors. J. Med. Chem. 1996, 39, 3217-3227.
7. Cushman, M.; Casimiro-Garcia, A.; Williamson, K.; Rice, W. G. Synthesis of a Non-Nucleoside Reverse Transcriptase Inhibitor in the Alkenyldiarylmethane (ADAM) Series with Optimized Potency and Therapeutic Index. Bioorg. Med. Chem. Lett. 1998, 8, 195-198.
8. Cushman, M.; Casimiro-Garcia, A.; Hejchman, E.; Ruell, J. A.; Huang, M.; Schaeffer, C. A.; Williamson, K.; Rice, W. G.; Buckheit, R. W. J. New Alkenyldiarylmethanes with Enhanced Potencies as Anti-HIV Agents Which Act as Non-Nucleoside Reverse Transcriptase Inhibitors. J. Med. Chem. 1998, 41, 2076-2089.
9. Casimiro-Garcia, A.; De Clercq, E.; Pannecouque, C.; Witvrouw, M.; Stup, T. L.; Turpin, J. A.; Buckheit, R. W. J.; Cushman, M. Synthesis and Anti-HIV Activity of Cosalane Analogues Incorporating Nitrogen in the Linker Chain. Unpublished results, 1999.
10. Cushman, M.; Golebiewski, W. M.; McMahon, J. B.; Buckheit, R. W. J.; Clanton, D. J.; Weislow, O.; Haugwitz, R. D.; Bader, J.; Graham, L.; Rice, W. G. Design, Synthesis, and Biological Evaluation of Cosalane, a Novel anti-HIV Agent which Inhibits Multiple Features of Virus Replication. J. Med. Chem. 1994, 37, 3040-3050.
11. Sorensen, S. J.; Soransen, N. A. Studies Related to Naturally Occurring Acetylenic Compounds. XXXIII. A Preliminary Investigation of Coreopsis gigantea. Acta Chem. Scand. 1966, 20, 992-1002.
12. Hooz, J.; Giliani, H. H. S. A Rapid, Mild Procedure for the Preparation of Alkyl Chlorides and Bromides. Can. J. Chem. 1968, 46, 86-87.
13. Kocienski, P. J.; Cernigliaro, G.; Feldstein, G. A Synthesis of (±)-Methyl n-Tetradeca-trans-2,2,5-trienoate, an Allenic Ester Produced by the Male Dried Bean Beetle Acanthoscelodes obtectus (Say). J. Org. Chem. 1977, 42, 353-355.
14. Vaillancourt, V.; Cudahy, M. M. In Encyclopedia of Reagents for Organic Synthesis; Paquette, L. A., Ed.; John Wiley and Sons: New York, 1995; Vol. 5, pp 3307-3311.
15. Satchell, D. P. N.; Satchell, R. S. Acylation by Ketenes and Isocyanates. A Mechanistic Comparison. Chem. Soc. Rev. 1975, 4, 231-250.
16. Schartzapel, A. J.; Zhong, L.; Docampo, R.; Rodriguez, J. B.; Gros, E. G. Design, Synthesis, and Biological Evaluation of New Growth Inhibitors of Trypanosoma cruzi (Epimastigotes). J. Med. Chem. 1987, 40, 2314-2322.
17. Mancuso, A. J.; Swern, D. Activated Dimethyl Sulfoxide: Useful Reagents for Synthesis. Synthesis 1981, 165-185.
18. McMurry, J. E. Carbonyl-Coupling Reactions Using Low-Valent Titanium. Chem. Rev. 1989, 89, 1513-1524.
19. Fürstner, A.; Bogdavovic, B. New Developments in the Chemistry of Low Valent Titanium. Angew. Chem., Int. Ed. Engl. 1996, 35, 2442-469.
20. Müller, K.; Prinz, H. Antipsoriatic Anthrones with Modulated Redox Properties. 4. Synthesis and Biological Activity of Novel 9.10-Dihydro-1,8-dihydroxy-9-oxo-2-anthracenecarboxylic and -hydroxamin Acids. J. Med. Chem. 1997, 40, 2780-2787.
21. Eberle, M. K.; Kahle, G. G. Preparation of Functionalized Ketones via Low-Temperature Grignard Reaction. Tetrahedron Lett. 1980, 21, 2303-2304.
22. Corey, E. J.; Virgil, S. C. Enantioselective Total Synthesis of a Protosterol, 3b,20-Dihydroxyprotost-24-ene. J. Am. Chem. Soc. 1990, 112, 6429-6431.
23. Sterzycki, R. Pyridinium Tosylate, a Mild Catalyst for Formation and Cleavage of Dioxolane-Type Acetals. Synthesis 1979, 724-725.
24. Huckstep, M.; Taylor, R. J. K. A Convenient Method of Preparing the Leukotriene Precursor Methyl 5-Oxopentanoate. Synthesis 1982, 881-882.
25. Ma, J. C.; Dougherty, D. A. The Cation-π Interaction. Chem. Rev. 1997, 97, 1303-1324.
26. Ting, A. Y.; Shin, I.; Lucero, C.; Schultz, P. G. Energetic Analysis of an Engineered Cation-π Interaction in Staphylococcal Nuclease. J. Am. Chem. Soc. 1998, 120, 7135-7136.
27. Micklatcher, M. L.; Cushman, M. An Improved Method for the Synthesis of 3-Fluorosalicylic Acid with Application to the Synthesis of 3-Trifluoromethylsalicylic Acid. Unpublished results, 1999.
28. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M. J.; Breslin, H. J.; Raeymaeckers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J.; Schellekens, K.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and Selective Inhibition of HIV-1 Replication In Vitro by a Novel Series of TIBO Derivatives. Nature 1990, 343, 470-474.
29. Baba, M.; De Clercq, E.; Tanaka, H.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Umezu, K.; Nakashima, H.; Mon, S.; Shigeta, S.; Walker, R. T.; Miyasaka, T. Potent and Selective Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) by 5-Ethyl-6-phenylthiouracil Derivatives through Their Interaction with the HIV-1 Reverse Transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2356-2360.
30. Debyser, Z.; Pauwels, R.; Andries, K.; Desmyter, J.; Kukla, M.; Janssen, P. A. J.; De Clercq, E. An Antiviral Target on Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Revealed by Tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione Derivatives. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 1451-1455.
31. Balzarini, J.; Pérez-Pérez, M.-J.; San-Félix, A.; Camarasa, M.-J.; Bathurst, I. C.; Barr, P. J.; De Clercq, E. Kinetics of Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Analogue [2′,5′-Bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide)thymine (TSAO-T). J. Biol. Chem. 1992, 267, 11831.
32. White, E. L.; Buckheit, R. W. J.; Ross, L. J.; Germany, J. M.; Andries, K.; Pauwels, R.; Janssen, P. A.; Shannon, W. M.; Chirigos, M. A. A TIBO Derivative, R82913, is a Potent Inhibitor of HIV-1 Reverse Transcriptase with Heteropolymer Templates. Antiviral Res. 1991, 16, 257-266.
33. Ren, J.; Esnouf, R.; Garman, E.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Jones, Y.; Stuart, D.; Stammers, D. High-Resolution Sturctures of HIV-1 RT from Four RT-Inhibitor Complexes. Struct. Biol. 1995, 2, 293-302.
34. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A.; Hughes, S. H.; Arnold, E. Structure of HIV-1 RT/TIBO R 86183 Complex Reveals Similarity in the Binding of Diverse Nonnucleoside Inhibitors. Nature Struct. Biol. 1995, 2, 407-415.
35. Schäfer, W.; Friebe, W.-G.; Leinert, W.; Mertens, A.; Poll, T.; von der Saal, W.; Zilch, H.; Nuber, H.; Ziegler, M. L. Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase: Molecular Modeling and X-ray Structure Investigations. J. Med. Chem. 1993, 36, 726-732.
36. Ren, J.; Esnouf, R.; Hopkins, A.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. The structure of HIV-1 Reverse Transcriptase Complexed with 9-Chloro-TIBO: Lessons for Inhibitor Design. Structure 1995, 3, 915-926.
37. Hsiou, Y.; Das, K.; Ding, J.; Clark, A. D. J.; Kleim, J.-P.; Rosner, M.; Winkler, I.; Reiss, G.; Hughes, S. H.; Arnold, E. Structures of Tyr 1998Leu Mutant and Wild-Type HIV-1 Reverse Transcriptase Complexed with the Non-Nucleoside Inhibitor HBY 097: Inhibitor Flexibility is a Useful Disign Feature for Reducing Drug Resistance. J. Mol. Biol. 1998, 284, 313-323.
38. Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R. G.; Boyer, P. L.; Hughes, S. H.; Pauwels, R.; Andries, K.; Janssen, P. A.; Arnold, E. Locations of Anti-AIDS Drug Binding Sites and Resistance Mutations in the Three-dimensional Structure of HIV-1 Reverse Transcriptase. J. Mol. Biol. 1994, 243, 369-387.
39. Smerdon, S. J.; Jäger, J.; Wang, J.; Kohlstaedt, L. A.; Chirino, A. J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Structure of the Binding Site for Nonnucleoside Inhibitors of the Reverse Transcriptase of Human Immunodeficiency Type I. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3911-3915.
40. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal Structure at 3.5 Å Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor. Science 1992, 256, 1783-1790.
41. Ding, J.; Das, K.; Tantillo, C.; Zhang, W.; Clark, A. D. J.; Jessen, S.; Lu, X.; Hsiou, Y.; Jacobo-Molina, A.; Andries, K.; Pauwels, R.; Moereels, H.; Koymans, L.; Janssen, P. A. J.; Smith, R. H. J.; Koepke, M. K.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 Reverse Transcriptase in a Complex with the Nonnucleoside Inhibitor α-APA R 95845 at 2.8 A Resolution. Structure 1995, 3, 365-379.
42. De Clercq, E. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) for the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections: Strategies to Overcome Drug Resistance Development. Med. Res. Rev. 1996, 16, 125-157.
43. Pauwels, R.; Andries, K.; Debyser, Z.; Kukla, M. J.; Schols, D.; Breslin, H. J.; Woestenborghs, R.; Desmyter, J.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. New Tetrahydroimidazo[4,5,1-jk][1,4]-Benzodiazepin-2(1H)-One and -Thione Derivatives are Potent Inhibitors of Human Immunodeficiency Virus Type 1 Replication and are Synergistic with 2′,3′-Dideoxynucleoside Analogues. Antimicrob. Agents Cehmother. 1994, 38, 2863-2870.
44. Goldman, M. E.; O'Brien, J. A.; Ruffing, T. L.; Schlief, W. A.; Sardana, V. V.; Byrnes, V. W.; Condra, J. H.; Hoffman, J. M.; Emini, E. A. A Nonnucleoside Reverse Transcriptase Inhibitor Active on Human Immunodeficiency Virus Type 1 Isolates Resistant to Related Inhibitors. Antimicrob. Agents Chemother. 1993, 37, 947-949.
45. Das, K; Ding, J.; Hsiou, Y.; Clark, A. D. J.; Moereels, H.; Koymans, L.; Adries, K.; Pauwels, R.; Janssen, P. A. J.; Boyer, P. L.; Clark, P.; Smith, R. H. J.; Smith, M. B. K.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Crystal Structure of 8-Cl and 9-Cl TIBO Complexed with Wild-type HIV-1 RT and 8-Cl TIBO Complexed with the Tyr 181Cys HIV-1 RT Drug-resistant Mutant. J. Mol. Biol. 1996, 264, 1085-1100.
46. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K; Stuart, D. I. Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relavant to the Design of Potent Non-Nucleoside Inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
47. Rice, W. G.; Bader, J. P. Discovery and in Vitro Development of AIDS Antiviral Drugs as Biopharmaceuticals. Adv. Pharmacol. (San Diego) 1995, 6, 389-438.
48. Buckheit, R. W. J.; Kinjerski, T. L.; Fliakas-Boltz, V.; Russell, J. D.; Stup, T. L.; Pallansch, L. A.; Brouwer, W. G.; Dao, D. C.; Harrison, W. A.; Schultz, R. J.; Bader, J. P.; Yang, S. S. Structure-Activity and Cross-Resistance Evaluations of a Series of Human Immunodeficiency Virus Type 1-Specific Compounds Related to Oxathiin Carboxanilide. Antimicrob. Agents Chemother. 1995, 39, 2718-2727.